Content
Frontiers of Medicine >> 2022, Volume 16, Issue 5 doi: 10.1007/s11684-021-0916-8
Anlotinib as third- or further-line therapy for short-term relapsed small-cell lung cancer: subgroup analysis of a randomized phase 2 study (ALTER1202)
Abstract
Keywords
anlotinib ; chemotherapy ; short-term relapsed ; small-cell lung cancer
Content